# RegoNivo vs Standard of Care Chemotherapy in AGOC

> **NCT04879368** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **Australasian Gastro-Intestinal Trials Group** · enrollment: 450 (estimated)

## Conditions studied

- Gastro-Oesophageal Cancer

## Interventions

- **DRUG:** Regorafenib
- **BIOLOGICAL:** Nivolumab
- **DRUG:** Docetaxel
- **DRUG:** Paclitaxel
- **DRUG:** Irinotecan
- **DRUG:** Trifluridine/Tipracil

## Key facts

- **NCT ID:** NCT04879368
- **Lead sponsor:** Australasian Gastro-Intestinal Trials Group
- **Sponsor class:** NETWORK
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2021-06-01
- **Primary completion:** 2025-07-09
- **Final completion:** 2026-06-01
- **Target enrollment:** 450 (ESTIMATED)
- **Last updated:** 2025-07-17

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04879368

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04879368, "RegoNivo vs Standard of Care Chemotherapy in AGOC". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04879368. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*